首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1461326

腫瘤藥物市場，依配銷通路、藥物類型、癌症類型、治療方法、給藥途徑、地理位置。

Oncology Drugs Market, By Distribution Channel, Drug Type, Cancer Type, By Therapy, By Route of Administration, By Geography .

出版日期: 2024年03月19日 | 出版商:

Coherent Market Insights | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年腫瘤藥物市值為2,315.6億美元，預計到2031年將達到5,329.1億美元，2024年至2031年年複合成長率（CAGR）為12.6%。

報告範圍		報告詳情
基準年：	2023年	2023/2024 年市場規模：	2315.6 億美元
歷史數據：	2019年至2023年	預測期：	2024年至2031年
預測期間 2023/2024 至 2030/2031 年複合成長率：	12.60%	2030/2031 價值預測：	5329.1 億美元

腫瘤藥物市場佔有率 (%)，依地區，2024 年

腫瘤藥物是指用於治療癌性腫瘤的藥物。由於各種癌症盛行率不斷上升，過去幾年全球腫瘤藥物市場一直穩定成長。據世界衛生組織稱，自2000年以來，癌症負擔幾乎加倍，預計到2040年全球癌症負擔將增加50%。主要因素用於腫瘤藥物。此外，老年人口的成長和生活習慣的改變，如吸煙、飲酒、不良飲食和缺乏體力活動，也增加了癌症的風險，從而增加了腫瘤藥物的銷售。新型藥物分子和療法的強大管道以及標靶療法的出現正在進一步促進市場擴張。然而，高昂的治療成本仍然是一個瓶頸，限制了癌症藥物的更廣泛採用。

市場動態：

全球腫瘤藥物市場受到全球各種癌症類型盛行率上升的推動。根據提供全球癌症統計數據的互動式網路平台 GLOBOCAN 的數據，2020 年全球約有 1,930 萬新發癌症病例，1,000 萬人因癌症死亡。對標靶治療的需求不斷成長以及學名藥的容易獲得為市場提供了巨大的成長機會。然而，嚴格的監管政策、藥物開發的高研發成本以及臨床試驗中藥物失敗頻繁等因素阻礙了市場的成長。此外，重磅藥物的專利到期對主要參與者的收入產生負面影響。儘管如此，亞太地區的新興市場正在開闢新的途徑，在意識不斷增強、醫療保健支出和對優質癌症治療的需求的推動下，提供潛在的未來機會。

研究的主要特點：

該報告對全球腫瘤藥物市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它闡明了不同區隔市場的潛在收入成長機會，並解釋了該市場有吸引力的投資主張矩陣。
這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
它根據以下參數描述了全球腫瘤藥物市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球腫瘤藥物市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
利害關係人可以透過用於分析全球腫瘤藥物市場的各種策略矩陣輕鬆做出決策。

介紹
北美洲
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地區
歐洲
英國
德國
義大利
法國
西班牙
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
東協
澳洲
韓國
亞太地區其他地區
中東
海灣合作理事會
以色列
中東其他地區
非洲
北非
中非
南非

第 11 章：競爭格局

熱圖分析
公司簡介
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Bristol-Myers Squibb
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo

第 12 章：分析師觀點

命運之輪
分析師觀點
連貫的機會圖

第 13 章：參考文獻與研究方法

參考
研究方法論

簡介目錄

Product Code: CMI2332

The oncology drugs market is estimated to be valued at USD 231.56 Bn in 2024 and is expected to reach USD 532.91 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 231.56 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	12.60%	2030/2031 Value Projection:	US$ 532.91 Bn

Oncology Drugs Market Share (%), By Region, 2024

Oncology drugs refer to medications that are used for treating cancerous tumors. The global oncology drugs market has been witnessing steady growth over the past few years owing to the rising prevalence of various types of cancers. According to the World Health Organization, the cancer burden has nearly doubled since 2000 and is expected to grow by 50% globally by 2040. The increasing incidences of lung cancer, colorectal cancer, breast cancer, and prostate cancer are the major factors fueling the demand for oncology drugs. Furthermore, the growing geriatric population and changing lifestyle habits such as tobacco smoking, alcohol consumption, poor diet, and lack of physical activity have also raised the risk of developing cancer which has augmented the sales of oncology medications. A robust pipeline of novel drug molecules and therapies along with the emergence of targeted therapies are further catalyzing market expansion. However, high treatment cost remains a bottleneck, restraining the broader adoption of cancer medications.

Market Dynamics:

The global oncology drugs market is driven by the rising prevalence of various cancer types worldwide. As per GLOBOCAN, an interactive web-based platform presenting global cancer statistics, there were around 19.3 million new cancer cases and 10 million cancer deaths globally in 2020. Lung cancer remains the leading cause of cancer death. The increasing demand for targeted therapies and easy availability of generic medications are providing huge growth opportunities in the market. However, factors such as stringent regulatory policies, high R&D costs involved in drug development, and frequent drug failures in clinical trials are impeding the market growth. Furthermore, patent expiry of blockbuster drugs is negatively impacting the revenues of major players. Nonetheless, emerging markets in Asia Pacific are opening up new avenues by offering potential future opportunities driven by growing awareness, healthcare spending, and demand for quality cancer treatment.

Key Features of the Study:

This report provides an in-depth analysis of the global oncology drugs market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, BeiGene LTD, Astellas Pharma Inc., AbbVie Inc., Takeda Pharmaceutical Company, and Daiichi Sankyo
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology drugs market

Market Segmentation

Drug Type
- Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
- Targeted Drugs
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- Others
- Hormonal Drugs
- Ovarian Function Blockers
- Estrogen Production Blockers
- Others
Cancer Type:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Bladder Cancer
- Other
Therapy:
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
Route of Administration:
- Oral
- Parental
- Intramuscular
- Intravenous
- Subcutaneous
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- F.Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Preview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Therapy
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Pipeline Analysis
Patent Expiry List (2017-2030)
Investments for R&D
Reimbursement Scenario
Mergers & Acquisitions
Collaborations
Epidemiology
PEST Analysis

4. Global Oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic:

Overall Impact
COVID-19 Impact on the Market

5. Global Oncology Drugs Market, By Drug Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Cytotoxic Drug
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Ovarian Function Blockers
Estrogen Production Blockers
Others
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Oncology Drugs Market, By Cancer Type,2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Breast Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Colorectal Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Blood Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Bladder Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Oncology Drugs Market, By Therapy, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Oncology Drugs Market, By Route of Administration, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Parental
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Intramuscular
- Intravenous
- Subcutaneous

9. Global Oncology Drugs Market, By Distribution Channel, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

10. Global Oncology Drugs Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
North Africa
Central Africa
South Africa

11. Competitive Landscape

Heat Map Analysis
Company Profile
- Pfizer Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Bristol-Myers Squibb
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo